In the present study, we examined the changes that occur with age in anti-idiotype-blocked, hapten-augmentable PFC in the mucosal-associated lymph nodes (MLN and BLN) and spleen of various strains of mice. 2-month-old 129/J, AKR/J, and C57L/J mice had a high percentage of hapten-augmentable PFC in their spleen, MLN, and BLN; however, by 6–11 months these values had declined considerably in the spleen, while mucosal values remained high. In contrast, 2-month-old C57BL/6J, DBA/2J, and C3H/HeJ mice had a low percentage of hapten-augmentable PFC in their spleen, MLN, and BLN; but by 6–11 months these values had increased considerably in the spleen, while mucosal values remained low. CBA/J and SJL/J mice maintained high and low levels, respectively, of hapten-augmentable PFC in their spleens, MLN, and BLN over the age span. NZB/BinJ mice were found to be low producers in the spleen, but high in the MLN and BLN at 2 and 6 months of age. These data indicate that there are strain differences in the development of auto-anti-idiotypic antibody regulation with age.

Keywords:
Auto-anti-idiotypic regulation, Mucosal immunity
This content is only available via PDF.
© 1985 S. Karger AG, Basel
1985
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.